Literature DB >> 28447005

Future directions in esophageal cancer therapy.

Ori Wald1, Brandon Smaglo2, Henry Mok3, Shawn S Groth1.   

Abstract

Resection techniques for esophageal carcinoma continue to evolve, from endoscopic mucosal resection or endoscopic submucosal dissection for early stage disease to standard and robot-assisted minimally invasive esophagectomy as part of multimodal therapy for locally advanced disease. Though currently limited to assessing conduit perfusion and sentinel lymph nodes, embedded technology in the robotic surgical platform will likely play an expanded role during esophagectomy in the future. The use of targeted therapies, checkpoint inhibitors, engineered immune cell therapy, and cancer vaccines show promise in the treatment of systemic disease. Radiation therapy techniques are becoming increasingly sophisticated and they may play a more active role in stage IV disease in the future.

Entities:  

Keywords:  Esophageal neoplasms; drug therapy; esophagectomy; immunotherapy; radiotherapy

Year:  2017        PMID: 28447005      PMCID: PMC5387153          DOI: 10.21037/acs.2017.02.01

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN: 2225-319X


  39 in total

1.  FDA Approval Summary: Ramucirumab for Gastric Cancer.

Authors:  Sandra J Casak; Ibilola Fashoyin-Aje; Steven J Lemery; Lillian Zhang; Runyan Jin; Hongshan Li; Liang Zhao; Hong Zhao; Hui Zhang; Huanyu Chen; Kun He; Michele Dougherty; Rachel Novak; Sarah Kennett; Sachia Khasar; Whitney Helms; Patricia Keegan; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2015-06-05       Impact factor: 12.531

2.  Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays.

Authors:  F M Selaru; T Zou; Y Xu; V Shustova; J Yin; Y Mori; F Sato; S Wang; A Olaru; D Shibata; B D Greenwald; M J Krasna; J M Abraham; S J Meltzer
Journal:  Oncogene       Date:  2002-01-17       Impact factor: 9.867

3.  Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials.

Authors:  Vera Oppedijk; Ate van der Gaast; Jan J B van Lanschot; Pieter van Hagen; Rob van Os; Caroline M van Rij; Maurice J van der Sangen; Jannet C Beukema; Heidi Rütten; Patty H Spruit; Janny G Reinders; Dick J Richel; Mark I van Berge Henegouwen; Maarten C C M Hulshof
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

4.  Intraoperative near-infrared fluorescence imaging as an adjunct to robotic-assisted minimally invasive esophagectomy.

Authors:  Inderpal S Sarkaria; Manjit S Bains; David J Finley; Prasad S Adusumilli; James Huang; Valerie W Rusch; David R Jones; Nabil P Rizk
Journal:  Innovations (Phila)       Date:  2014 Sep-Oct

5.  Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

Authors:  J Randolph Hecht; Yung-Jue Bang; Shukui K Qin; Hyun C Chung; Jianming M Xu; Joon O Park; Krzysztof Jeziorski; Yaroslav Shparyk; Paulo M Hoff; Alberto Sobrero; Pamela Salman; Jin Li; Svetlana A Protsenko; Zev A Wainberg; Marc Buyse; Karen Afenjar; Vincent Houé; Agathe Garcia; Tomomi Kaneko; Yingjie Huang; Saba Khan-Wasti; Sergio Santillana; Michael F Press; Dennis Slamon
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

6.  Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial.

Authors:  Surya S A Y Biere; Mark I van Berge Henegouwen; Kirsten W Maas; Luigi Bonavina; Camiel Rosman; Josep Roig Garcia; Suzanne S Gisbertz; Jean H G Klinkenbijl; Markus W Hollmann; Elly S M de Lange; H Jaap Bonjer; Donald L van der Peet; Miguel A Cuesta
Journal:  Lancet       Date:  2012-05-01       Impact factor: 79.321

7.  Gene expression profiles in esophageal adenocarcinoma predict survival after resection.

Authors:  Arjun Pennathur; Liqiang Xi; Virginia R Litle; William E Gooding; Alyssa Krasinskas; Rodney J Landreneau; Tony E Godfrey; James D Luketich
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02       Impact factor: 5.209

8.  High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine.

Authors:  Takuro Saito; Hisashi Wada; Makoto Yamasaki; Hiroshi Miyata; Hiroyoshi Nishikawa; Eiichi Sato; Shinichi Kageyama; Hiroshi Shiku; Masaki Mori; Yuichiro Doki
Journal:  Vaccine       Date:  2014-09-13       Impact factor: 3.641

9.  British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.

Authors:  Rebecca C Fitzgerald; Massimiliano di Pietro; Krish Ragunath; Yeng Ang; Jin-Yong Kang; Peter Watson; Nigel Trudgill; Praful Patel; Philip V Kaye; Scott Sanders; Maria O'Donovan; Elizabeth Bird-Lieberman; Pradeep Bhandari; Janusz A Jankowski; Stephen Attwood; Simon L Parsons; Duncan Loft; Jesper Lagergren; Paul Moayyedi; Georgios Lyratzopoulos; John de Caestecker
Journal:  Gut       Date:  2013-10-28       Impact factor: 23.059

10.  Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.

Authors:  Ming Lu; Xicheng Wang; Lin Shen; Jun Jia; Jifang Gong; Jie Li; Jian Li; Yan Li; Xiaotian Zhang; Zhihao Lu; Jun Zhou; Xiaodong Zhang
Journal:  Cancer Sci       Date:  2016-03-28       Impact factor: 6.716

View more
  8 in total

1.  Impact of Radiation on Cardiovascular Outcomes in Older Resectable Esophageal Cancer Patients With Medicare.

Authors:  Reith R Sarkar; Ahmadreza Hatamipour; Neil Panjwani; P Travis Courtney; Daniel R Cherry; Mia A Salans; Anthony T Yip; Brent S Rose; Daniel R Simpson; Matthew P Banegas; James D Murphy
Journal:  Am J Clin Oncol       Date:  2021-06-01       Impact factor: 2.787

2.  Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study.

Authors:  Ken Kato; Takashi Ura; Wasaburo Koizumi; Satoru Iwasa; Chikatoshi Katada; Mizutomo Azuma; Satoshi Ishikura; Yoshinori Nakao; Hiroshi Onuma; Kei Muro
Journal:  Cancer Sci       Date:  2018-02-15       Impact factor: 6.716

3.  Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: Is esophagectomy always necessary? A systematic review and meta-analysis.

Authors:  Jun Wang; Jianjun Qin; Shaowu Jing; Qing Liu; Yunjie Cheng; Yi Wang; Feng Cao
Journal:  Thorac Cancer       Date:  2018-10-01       Impact factor: 3.500

4.  Sub-region based radiomics analysis for survival prediction in oesophageal tumours treated by definitive concurrent chemoradiotherapy.

Authors:  Congying Xie; Pengfei Yang; Xuebang Zhang; Lei Xu; Xiaoju Wang; Xiadong Li; Luhan Zhang; Ruifei Xie; Ling Yang; Zhao Jing; Hongfang Zhang; Lingyu Ding; Yu Kuang; Tianye Niu; Shixiu Wu
Journal:  EBioMedicine       Date:  2019-05-23       Impact factor: 8.143

Review 5.  The Critical Role of Hypoxic Microenvironment and Epigenetic Deregulation in Esophageal Cancer Radioresistance.

Authors:  Catarina Macedo-Silva; Vera Miranda-Gonçalves; Rui Henrique; Carmen Jerónimo; Isabel Bravo
Journal:  Genes (Basel)       Date:  2019-11-14       Impact factor: 4.096

6.  Minimal invasive versus open esophagectomy for patients with esophageal squamous cell carcinoma after neoadjuvant treatments.

Authors:  Dongni Chen; Weidong Wang; Junxian Mo; Qiannan Ren; Huikai Miao; Youfang Chen; Zhesheng Wen
Journal:  BMC Cancer       Date:  2021-02-09       Impact factor: 4.430

7.  Practical value of identifying circulating tumor cells to evaluate esophageal squamous cell carcinoma staging and treatment efficacy.

Authors:  Weipeng Chen; Yin Li; Dongfeng Yuan; Yinjie Peng; Jianjun Qin
Journal:  Thorac Cancer       Date:  2018-06-12       Impact factor: 3.500

8.  GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma.

Authors:  Jovana R Gotovac; David Sh Liu; Michael J Yates; Julia V Milne; Arthi A Macpherson; Kaylene J Simpson; Guy D Eslick; Catherine Mitchell; Cuong P Duong; Wayne A Phillips; Nicholas J Clemons
Journal:  J Pathol       Date:  2020-09-15       Impact factor: 7.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.